A Comprehensive Exploration of the lncRNA CCAT2: A Pan-Cancer Analysis Based on 33 Cancer Types and 13285 Cases

Table 2

Combinations of data evaluating the associations of CCAT2 with the clinicopathological characteristics of the study patients.

Clinicopathological parameters	Studies ()	Test/event total		Control/event total		Model	OR (95% CI)	Test for heterogeneity		value
								Age (old/young)	15 (1649)		449	859	405	790	Fixed	1.04 (0.85-1.27)	0.0%	0.741	0.714
Gender (male/female)	11 (1201)	392	764	221	437	Fixed	1.06 (0.84-1.35)	0.0%	0.996	0.621
Tumor size (large/small)	15 (1656)	418	761	435	895	Random	1.50 (1.03-2.20)	70.4%	0.000	0.036
Clinical stage (advanced/early)	14 (1584)	568	891	258	693	Fixed	3.09 (2.49-3.83)	19.8%	0.238	0.000
T (T3-T4/T1-T2)	6 (579)	145	231	147	348	Fixed	2.37 (1.68-3.37)	10.8%	0.347	0.000
N (N1-N3/N0)	12 (1356)	399	602	306	754	Random	3.33 (2.29-4.84)	55.8%	0.009	0.000
M (M1/M0)	7 (690)	118	142	224	548	Fixed	6.85 (4.23-11.11)	47.1%	0.078	0.000
Differentiation (poorly/well)	11 (1331)	324	616	349	715	Random	1.17 (0.75-1.81)	69.1%	0.000	0.484